While the long-term bull market has been largely attributable to the influx of money into index ETFs, which has been successful for some time, due to Covid a new paradigm shift has occurred. That paradigm is one that no longer says growth and low unemployment will alone catapult the market forward due to a relatively healthy capitalist system. Instead, we've learned over the past few months, that humanity can be challenged by complex viruses and if we are not more prepared, we are all at risk.
Finding Investment Themes that make sense and staying with them, until they don't. It's all your call, your opinion, your perspective on where you fit in, what products and services you value and whether those companies reflect not only your perception of the world, but also if those companies are growing. The above discussion regarding how I'm viewing the new paradigm causes me to focus on my first investment theme, Scientific Research to further strengthen and improve the overall health of humanity. Coming off of selling all of my equity holdings in early March, just after the covid crash, and then starting to reinvest that cash slowly back in in late March, a few months ago, I started investing more heavily into pharama and biotech, more than ever before. This is because investing in Science is not only good for humanity and life on earth as we know it, it is also good for business and returns. In addition the disparity of valuation that is being seen within that sector, is greater than I've ever experienced.
I'm currently allocated to Regeneron, CRISPR, Illumina, JNJ, Bristol, Abbott and Masimo - I believe genetic editing and immunization and treatment for molecular and biological disease and treatment. Covid falls into the biologic. All of these companies, from what I've read show great progress with fda approved drugs in pipeline for re
More on Remote Software
DOCUsign, MSFT, FB, SNAP,
This portfolio shows that it performs very well when the markets are uncertain and when the "covid trade" as its been coined which has been favorable to
No comments:
Post a Comment